Immunome, Inc. (IMNM)
NasdaqCM · USD · Healthcare · Biotechnology
$17.89 (-0.56%) as of
Key statistics
- Market cap
- 2.11B
- Forward P/E
- -7.28
- EPS (TTM)
- -2.52
- Dividend yield
- 0.00%
- 52-week range
- 14.64 – 30.06
- Beta
- 2.56
- Profit margin
- 0.00%
- Analyst target
- $35.33
- Volume
- 910.52k
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bothell, WA, United States
- Employees
- 247
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.